Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition
Name
12195_2018_Article_542.pdf
Size
1.49 MB
Format
Adobe PDF
Checksum (MD5)
3c83ef5162e4ad307e6316d1c8380d05
Author(s)
Claas, Allison Mary
Atta, Lyla H.
Gordonov, Simon
Meyer, Aaron Samuel
Lauffenburger, Douglas A
Date Issued
July 2018
Journal
Cellular and Molecular Bioengineering
Publisher
Springer US
Citation
Claas, Allison M., Lyla Atta, Simon Gordonov, Aaron S. Meyer, and Douglas A. Lauffenburger. “Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition.” Cellular and Molecular Bioengineering (July 26, 2018).
Version
Final published version
Abstract
Introduction - Targeted cancer therapeutics have demonstrated more limited clinical efficacy than anticipated, due to both intrinsic and acquired drug resistance. Underlying mechanisms have been largely attributed to genetic changes, but a substantial proportion of resistance observations remain unexplained by genomic properties. Emerging evidence shows that receptor tyrosine kinase (RTK) reprogramming is a major alternative process causing targeted drug resistance, separate from genetic alterations. Hence, the contributions of mechanisms leading to this process need to be more rigorously assessed.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Biology
Massachusetts Institute of Technology. Department of Chemical Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1007/s12195-018-0542-y
